Respiratory CRO Services
Respiratory Assays
Respiratory CRO Services for Preclinical Drug Discovery Research
Cellomatics is a specialist respiratory CRO providing preclinical in vitro airway models to support respiratory drug discovery programmes. As a contract research organisation focused on respiratory diseases, we support biotechnology and pharmaceutical companies evaluate their therapeutic candidates using disease-relevant cellular systems and scalable screening technologies.
Our respiratory research platforms combine human airway and lung cell models, immune cell assays, and advanced imaging approaches to investigate disease mechanisms and therapeutic responses across conditions such as asthma, airway sensitisation/hyper-responsiveness, COPD, pulmonary fibrosis, viral airway infections, pulmonary hypertension and allergic airway disease.
By integrating disease-relevant biology with scalable screening workflows, Cellomatics helps partners accelerate target validation, hit identification and lead optimisation in respiratory drug discovery. Cellomatics provides comprehensive drug discovery outsourcing services to support respiratory research programmes from target validation through preclinical evaluation.
What is a respiratory CRO?
A respiratory contract research organisation (CRO) provides specialised scientific services that support the discovery and development of therapies targeting airway diseases.
These organisations work as research partners for biotechs and pharmaceutical companies, providing access to disease-relevant experimental models, screening platforms and translational expertise that enable the evaluation of new drug candidates before clinical development.
At Cellomatics, our respiratory CRO services focus on human-relevant in vitro models and cellular assays designed to replicate key biological processes involved in respiratory disease. These systems allow researchers to study disease mechanisms, evaluate compound activity and generate robust data that supports decision-making throughout early drug discovery.
Respiratory disease expertise
Cellomatics supports respiratory research programmes across a range of airway diseases. Our scientific platforms combine human lung and airway cell systems, immune cell models and scalable screening technologies to generate high-quality data for respiratory drug discovery.
Our flexible respiratory assay systems can be adapted to specific targets, pathways and compound screening strategies, allowing researchers to investigate disease mechanisms, inflammatory signalling and therapeutic responses across multiple pulmonary conditions. Our expertise in drug discovery in clinical research enables researchers to generate translational data that supports the development of novel respiratory therapeutics.
Asthma and Airway Inflammation
Chronic Obstructive Pulmonary Disease
Pulmonary Fibrosis
Allergic Respiratory Conditions
Viral Respiratory Infections
Bronchial Epithelial Stress Responses
Precision Cut Lung Slices & Fibrosis Model
Expert insight: asthma and airway inflammation research
We offer specialised asthma drug discovery assays designed to investigate disease mechanisms and evaluate potential therapeutic candidates. To explore current scientific perspectives in this area, listen to our podcast featuring Dr Eleni Birli, who discusses her research on asthma and airway inflammation and how emerging scientific insights are shaping respiratory disease research.
Screening and assay capabilities
Cellomatics provides advanced screening and assay capabilities designed to support respiratory drug discovery programmes from early target validation through lead optimisation. Our platforms combine disease-relevant biology with scalable experimental systems, enabling detailed evaluation of compound activity, mechanism of action, and therapeutic potential. By integrating cell-based respiratory models, imaging technologies, and automated workflows, we generate high-quality, reproducible data to guide confident decision-making across discovery pipelines. Our respiratory disease research services help biotechnology and pharmaceutical companies accelerate the development of treatments for complex pulmonary disorders.
Cell-Based Respiratory Screening
High-Throughput & High-Content Screening
Human-relevant in vitro respiratory models
Cellomatics develops human-relevant in vitro respiratory models designed to replicate key biological processes within the airway environment. These systems use well-characterised human respiratory cells, including airway epithelial and smooth muscle/myofibroblastmodels, to capture clinically relevant aspects of respiratory disease biology.
As a human-relevant disease models CRO, Cellomatics develops clinically relevant in vitro systems that improve the predictive value of preclinical studies. Our models allow detailed investigation of inflammatory signalling, immune responses and tissue remodelling associated with respiratory disorders. By integrating human cell biology with advanced imaging and assay technologies, we generate translational data that helps researchers better predict therapeutic responses during respiratory drug development.
Why choose Cellomatics as your respiratory CRO?
Cellomatics provides specialised expertise in in vitro respiratory models to support drug discovery programmes targeting lung and airway diseases.
Our scientific teams work closely with biotechnology and pharmaceutical partners to design assay strategies aligned with specific targets, mechanisms and project goals. Our lung disease assay models are designed to replicate key pathological features of respiratory disorders and support mechanism-of-action studies.
Key advantages include:
- Human-relevant respiratory models using well-characterised lung and airway cell systems
- Flexible assay development tailored to specific targets, pathways, and screening needs
- Collaborative scientific support delivering robust, decision-driving preclinical data
Request more information
Cellomatics operates as a preclinical CRO, delivering robust assay data and customised research solutions for respiratory drug development programmes. For a more in depth look at our respiratory expertise, click the button below to gain access to our Respiratory Hub with a detailed look at our data sets and offering.
FAQ's
These services focus on studying lung and airway diseases using biologically relevant models to understand disease mechanisms and evaluate new therapies.
Such CROs, including Cellomatics, develop and apply advanced in vitro and ex vivo models—leveraging primary human cells, co-culture systems, and disease-relevant platforms—to closely mimic human physiology and improve the prediction of clinical outcomes.
They enable early-stage evaluation of drug efficacy in systems that reflect human biology, improving decision-making and reducing development risk.
By incorporating primary human cells and complex co-culture systems, they better replicate in vivo conditions and generate more reliable data.
Models include airway epithelial cultures, lung fibroblast systems, and ex vivo tissue models designed to mimic inflammation and fibrosis. At Cellomatics, these are implemented using primary human cells, air–liquid interface (ALI) cultures, and co-culture systems to better replicate respiratory disease biology and improve translational relevance.
These services support asthma, COPD, pulmonary fibrosis, and infection-driven respiratory conditions. At Cellomatics, these are combined with functional and molecular assays for deeper insights.
Cellomatics offers a range of respiratory CRO services designed to support early drug discovery and translational research. Common respiratory research services include in vitro respiratory disease models, cell-based screening assays, primary human cell assays, immune cell studies, and high-content or high-throughput screening. These platforms enable detailed evaluation of compound activity, mechanism of action, and therapeutic potential in lung and airway disease models.
Yes. Cellomatics supports preclinical respiratory drug discovery programmes, helping biotech and pharmaceutical teams evaluate therapeutic candidates before clinical development. Our models generate robust data to guide target validation, compound screening, and lead optimisation.
Our research platforms support studies in multiple respiratory diseases, including asthma, airway inflammation, pulmonary fibrosis, COPD, viral infection and allergic respiratory conditions.
Yes. We provide cell-based respiratory screening assays, alongside high-throughput and high-content screening platforms suitable for both targeted studies and larger compound libraries.
Yes. Cellomatics delivers respiratory CRO services in the UK, supporting global partners with flexible, collaborative preclinical research services.
Request a consultation with Cellomatics Biosciences today
The early-stage drug discovery CRO services support clients in advancing promising respiratory therapies through efficient and scientifically rigorous testing strategies. Our experienced team of in vitro laboratory scientists will work with you to understand your project and provide a bespoke project plan with a professional, flexible service and a fast turnaround time.
To request a consultation where we can discuss your exact requirements, please contact Cellomatics Biosciences.
